Data / Form D filings / Outlook Therapeutics, Inc.
Outlook Therapeutics, Inc.: Form D filings
Outlook Therapeutics, Inc., a biotechnology company in Iselin, NJ, filed 13 Form D notices with the SEC between 2015 and 2026. The latest, on May 7, 2026, reports an offering of $5 million with nothing sold yet to 2 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 111 S. WOOD AVENUE UNIT #100, Iselin, NJ, 08830
- Phone
- (609) 619-3990
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1649989
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| May 7, 2026 | New notice | $5,000,000 | $0 | $5,000,000 | 2 | Apr 23, 2026 | sec.gov |
| Jan 27, 2025 | New notice | $31,977,359 | $0 | $31,977,359 | 10 | Jan 17, 2025 | sec.gov |
| Apr 16, 2024 | New notice | $13,250,005 | $5,000,002 | $8,250,003 | 1 | Apr 15, 2024 | sec.gov |
| Mar 29, 2024 | New notice | $159,000,000 | $60,000,000 | $99,000,000 | 21 | Mar 18, 2024 | sec.gov |
| Jan 6, 2023 | New notice | $1,031,510 | $1,031,510 | 1 | Dec 28, 2022 | sec.gov | |
| Jan 6, 2023 | New notice | $31,820,000 | $31,820,000 | 1 | Dec 28, 2022 | sec.gov | |
| Feb 12, 2021 | New notice | $4,013,627 | $4,013,627 | 2 | Feb 3, 2021 | sec.gov | |
| Jun 9, 2020 | New notice | $16,000,000 | $16,000,000 | 1 | Jun 2, 2020 | sec.gov | |
| Mar 11, 2020 | New notice | $7,971,155 | $7,971,155 | 7 | Feb 24, 2020 | sec.gov | |
| Sep 25, 2017 | New notice | $40,075,000 | $3,262,800 | $36,812,200 | 1 | Sep 11, 2017 | sec.gov |
| Dec 23, 2015 | New notice | $50,000,000 | $6,345,960 | $43,654,040 | 11 | Dec 8, 2015 | sec.gov |
| Oct 13, 2015 | New notice | $14,480,486 | $14,480,486 | 4 | Sep 28, 2015 | sec.gov | |
| Aug 10, 2015 | New notice | $31,050,000 | $31,050,000 | 7 | Jun 5, 2015 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Randy H. Thurman | Director | |
| Yezan Haddadin | Director | |
| Kurt J. Hilzinger | Director | |
| Lawrence A. Kenyon | Executive Officer, Director | |
| Faisal G. Sukhtian | Director | |
| Andong Huang | Director | |
| Gerd Auffarth | Director | |
| Julian Gangolli | Director |
Other biotechnology companies in New Jersey that filed recently
- Ensho Therapeutics, Inc. $7.3 million · Oct 15, 2026
- Xenon Ophthalmics Inc $3.3 million · Oct 6, 2026
- LISATA THERAPEUTICS, INC. $351.9 million · Oct 2, 2026
- Bullseye Biodevices, Inc. $1.3 million · Aug 10, 2026
- Hepion Pharmaceuticals, Inc. $3.1 million · Aug 5, 2026
Every Form D from the week of May 4, 2026 · All recent filings in New Jersey · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Outlook Therapeutics, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.